BIOA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-2.400.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$923.3MSmall cap
Wall Street coverage
$49.50median target· current $18.31 (+170.3%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.34
- P/S (TTM)
- 86.14
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -26.0%
- Operating margin
- -915.0%
- Revenue growth YoY
- 91.0%
- Dividend yield
- —
- Beta
- —
Last earnings
May 8, 2026 · Estimate $-0.71 · Reported $-0.52
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About BioAge Labs, Inc
Company profileBioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 5885 HOLLIS STREET, EMERYVILLE, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$923.3M
Shares outstanding$44.5M
52W high$24.00
52W low$4.07
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent